BioTelemetry (BEAT) Tops Q2 EPS by 2c; Raises Outlook

BioTelemetry (NASDAQ: BEAT) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $58.1 million versus the consensus estimate of $58.39 million.

Increases full year 2017 revenue guidance to $285 million to $290 million, with expected adjusted EBITDA of approximately 23% of revenue.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Constellation Brands (STZ) Tops Q1 EPS by 18c